Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Hook (up 12-5/8 to 33-1/8) and Genentech (up 10-1/2 to 44-3/4) led skyrocketing stocks on the "F-D-C" OTC Monthly Index in January. Joining a record-setting rally on the "Street," advancing stocks on the OTC Monthly Index outnumbered declining issues nearly seven to one as 34 stocks rose, five sank and two remained unchanged for the month. The rally lifted the OTC Index Composite 7.6% to its highest point since the summer of 1983. Hook's 12-point plus gain was generated by Rite-Aid's $31 a share offer for the 300-store Midwest chain on Jan. 30. The total purchase is valued at $136 mil. (see related T&G this issue). Genentech's 10 point vault in January led a broad resurgence among biotech stocks. Among the other biotech stocks jumping more than 30% in January were Immunex (up 3-1/4 to 9-1/2), Collaborative Research (up 1-1/2 to 5-5/8), Biogen (up 1-7/8 to 7-3/8), and Cetus (up 2-7/8 to 11-5/8). During the month, Genentech announced the successful completion of an R&D partnership to fund development of tumor necrosis factor. Two other groups on the OTC Index enjoying a broad run-up in January were the generic mfrs. and the drug whslrs. All four generic firms listed on the Index posted sizable gains in January as Mylan jumped 5-7/8 to 31-1/4; Zenith gained 4-1/4 to 23-3/4; Par gained 4 to 17; and LyphoMed rose 3-3/4 to 17-5/8. The Whslr. Component added over 16% in January led by FoxMeyer (up 5-1/2 to 27-3/4) and Bindley Western (up 4-7/8 to 24-3/4). Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts